Belantamab Mafodotin Combos Show Promise in Relapsed Multiple Myeloma Trial
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
Summary
This completed Phase 1/2 trial from GlaxoSmithKline evaluated belantamab mafodotin — an antibody-drug conjugate targeting BCMA — combined with two established multiple myeloma regimens. One group received belantamab with lenalidomide and dexamethasone continuously until disease progression. A second group received belantamab with bortezomib and dexamethasone for up to eight cycles, then continued on belantamab alone. The study enrolled patients who had relapsed or become refractory to at least one prior line of therapy. The primary focus was safety and tolerability, with clinical activity as a secondary goal. Results from this trial helped build the evidence base for belantamab mafodotin combinations now being explored in broader myeloma treatment strategies.
Detailed Summary
Multiple myeloma remains a challenging malignancy, particularly for patients who relapse or become refractory to standard therapies. Novel treatment combinations that can overcome resistance mechanisms are urgently needed to extend survival and improve quality of life for this population.
This Phase 1/2 trial (NCT03544281), sponsored by GlaxoSmithKline, investigated the safety, tolerability, and preliminary efficacy of belantamab mafodotin — an antibody-drug conjugate directed against B-cell maturation antigen (BCMA) — when combined with two well-established regimens. Arm A paired belantamab mafodotin with lenalidomide and dexamethasone, administered continuously until disease progression or intolerance. Arm B combined belantamab mafodotin with bortezomib and dexamethasone for up to eight cycles, after which patients transitioned to belantamab mafodotin monotherapy.
The trial enrolled participants with relapsed or refractory multiple myeloma who had received at least one prior line of approved therapy. Being a Phase 1/2 study, the primary endpoints centered on characterizing the safety and tolerability profile of these combinations, with clinical activity assessed as a key secondary outcome. The dual-arm design allowed head-to-head comparison of belantamab's compatibility with both immunomodulatory and proteasome inhibitor backbones.
Findings from this study carry important implications for the evolving myeloma treatment landscape. Belantamab mafodotin received FDA accelerated approval in 2020 for single-agent use in heavily pretreated myeloma, and combination data from trials like this one are critical for understanding how to integrate BCMA-targeted therapy earlier in the treatment algorithm.
However, several caveats apply. The abstract does not disclose specific efficacy or safety outcomes, making it impossible to assess response rates or adverse event frequencies. Additionally, the Phase 1/2 design limits the statistical power available to draw definitive conclusions about comparative effectiveness between the two arms.
Key Findings
- Phase 1/2 trial tested belantamab mafodotin with two standard myeloma regimens in relapsed/refractory patients.
- Arm A used continuous belantamab plus lenalidomide/dexamethasone; Arm B used bortezomib/dexamethasone for 8 cycles then monotherapy.
- Eligibility required at least one prior line of approved myeloma therapy, targeting a high-need relapsed population.
- Dual-arm design allows comparison of BCMA-targeted therapy across immunomodulatory and proteasome inhibitor backbones.
- Trial status is completed, contributing combination safety data to support broader belantamab mafodotin development.
Methodology
This was a Phase 1/2, two-arm, open-label trial sponsored by GlaxoSmithKline. Arm A assessed belantamab mafodotin with lenalidomide/dexamethasone continuously, while Arm B evaluated an 8-cycle combination with bortezomib/dexamethasone followed by belantamab monotherapy. The study enrolled adults with relapsed or refractory multiple myeloma with at least one prior line of therapy.
Study Limitations
The summary is based on the abstract only; specific efficacy, response rate, and adverse event data are not available. As a Phase 1/2 study, statistical power for comparative efficacy conclusions between arms is limited. Results from the completed trial have not been detailed in the available source, restricting interpretation of clinical significance.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.